B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis

Trial Profile

B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BeatMG
  • Most Recent Events

    • 11 Aug 2017 Primary endpoint (Percent of subjects that achieve a 75% reduction in mean daily prednisone dose in the 4 weeks prior to week 52) has been met as per the results published in the Neurology.
    • 11 Aug 2017 Primary endpoint (Myasthenia Gravis Status and Treatment Intensity (MGSTI)) has been met as per the results published in the Neurology
    • 11 Aug 2017 Results published in the Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top